A detailed history of Legal & General Group PLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 15,179,224 shares of ABBV stock, worth $2.69 Billion. This represents 0.64% of its overall portfolio holdings.

Number of Shares
15,179,224
Previous 15,179,224 -0.0%
Holding current value
$2.69 Billion
Previous $3 Billion -0.0%
% of portfolio
0.64%
Previous 0.64%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $16.1 Million - $19.6 Million
-98,256 Reduced 0.64%
15,179,224 $3 Billion
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $20.8 Million - $24.3 Million
134,239 Added 0.89%
15,277,480 $2.62 Billion
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $11.2 Million - $12.8 Million
-70,280 Reduced 0.46%
15,143,241 $2.76 Billion
Q4 2023

Feb 15, 2024

BUY
$137.6 - $154.97 $429 Million - $483 Million
3,118,987 Added 25.79%
15,213,521 $2.36 Billion
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $71.2 Million - $82.4 Million
-533,050 Reduced 4.22%
12,094,534 $1.8 Billion
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $98.2 Million - $122 Million
741,031 Added 6.23%
12,627,584 $1.7 Billion
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $21.5 Million - $24.7 Million
148,488 Added 1.27%
11,886,553 $1.89 Billion
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $73.7 Million - $88.4 Million
-533,001 Reduced 4.34%
11,738,065 $1.9 Billion
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $34.8 Million - $39.9 Million
-259,294 Reduced 2.07%
12,271,066 $1.65 Billion
Q2 2022

Aug 22, 2022

BUY
$137.62 - $174.96 $65.5 Million - $83.3 Million
476,257 Added 3.95%
12,530,360 $1.92 Billion
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $104 Million - $128 Million
784,446 Added 6.96%
12,054,103 $1.95 Billion
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $40.1 Million - $50.7 Million
-373,125 Reduced 3.2%
11,269,657 $1.53 Billion
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $49.3 Million - $56 Million
463,730 Added 4.15%
11,642,782 $1.26 Billion
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $20.3 Million - $22.6 Million
193,109 Added 1.76%
11,179,052 $1.26 Billion
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $30.1 Million - $33.2 Million
-294,397 Reduced 2.61%
10,985,943 $1.19 Billion
Q4 2020

Feb 12, 2021

BUY
$80.49 - $108.67 $36.4 Million - $49.1 Million
451,897 Added 4.17%
11,280,340 $1.21 Billion
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $27.5 Million - $32.2 Million
-319,749 Reduced 2.87%
10,828,443 $948 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $129 Million - $172 Million
1,755,024 Added 18.68%
11,148,192 $1.09 Billion
Q1 2020

May 14, 2020

BUY
$64.5 - $97.79 $16 Million - $24.2 Million
247,883 Added 2.71%
9,393,168 $716 Million
Q4 2019

Feb 13, 2020

BUY
$72.13 - $90.25 $13.4 Million - $16.7 Million
185,411 Added 2.07%
9,145,285 $810 Million
Q3 2019

Nov 13, 2019

BUY
$62.98 - $75.72 $6.68 Million - $8.03 Million
106,093 Added 1.2%
8,959,874 $678 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $7.85 Million - $10 Million
-119,553 Reduced 1.33%
8,853,781 $644 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $122 Million - $144 Million
1,586,937 Added 21.48%
8,973,334 $723 Million
Q4 2018

Feb 15, 2019

BUY
$77.85 - $96.01 $38.2 Million - $47.1 Million
490,348 Added 7.11%
7,386,397 $681 Million
Q3 2018

Nov 20, 2018

SELL
$88.91 - $98.84 $14 Million - $15.6 Million
-157,621 Reduced 2.23%
6,896,049 $652 Million
Q2 2018

Aug 10, 2018

SELL
$89.78 - $106.23 $49.2 Million - $58.2 Million
-548,337 Reduced 7.21%
7,053,670 $654 Million
Q1 2018

May 17, 2018

SELL
$92.01 - $123.21 $42.4 Million - $56.8 Million
-461,143 Reduced 5.72%
7,602,007 $720 Million
Q4 2017

Feb 13, 2018

BUY
$89.56 - $98.21 $722 Million - $792 Million
8,063,150
8,063,150 $780 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.